

17

about 140 mg/dl to about 200 mg/dl, and/or a baseline fasting HDL-C of about 10 mg/dl to about 60 mg/dl.

4. The method of claim 1, wherein said administering effects a reduction in fasting triglycerides of at least about 10% without increasing LDL-C by more than 5% in the subject.

5. The method of claim 1, wherein said administering effects a reduction in apolipoprotein B in the subject.

6. The method of claim 1, wherein said administering effects a reduction in VLDL-C in the subject.

7. The method of claim 1, wherein said administration effects reduction in fasting triglycerides of at least about 20% without increasing LDL-C in the subject.

8. The method of claim 1, wherein each capsule comprises about 950 mg of ethyl eicosapentaenoate.

9. The method of claim 1, wherein each capsule comprises about 975 mg of ethyl eicosapentaenoate.

10. The method of claim 1, wherein each capsule comprises about 1 g of ethyl eicosapentaenoate.

11. A method of reducing triglycerides in a subject having a fasting baseline triglyceride level of 500 mg/dl to about 1500 mg/dl comprising, administering orally to the subject 4 capsules per day, each capsule comprising about 900 mg to about 1 g of ethyl eicosapentaenoate and not more than about 3% docosahexaenoic acid or its esters, by weight of total fatty acids present, for a period of 12 weeks to effect a reduction in triglycerides in the subject compared to placebo control.

12. The method of claim 11 wherein the subject has a fasting baseline LDL-C from about 50 mg/dl to about 300 mg/dl.

18

13. The method of claim 11, wherein the subject has one or more of: a baseline fasting non-HDL-C of about 200 mg/dl to about 400 mg/dl, a baseline fasting total cholesterol of about 250 mg/dl to about 400 mg/dl, a baseline fasting VLDL-C of about 140 mg/dl to about 200 mg/dl, and/or a baseline fasting HDL-C of about 10 mg/dl to about 60 mg/dl.

14. The method of claim 11, wherein said administering effects a reduction in fasting triglycerides of at least about 10% without increasing LDL-C by more than 5% in the subject compared to placebo control.

15. The method of claim 11, wherein said administering effects a reduction in apolipoprotein B in the subject compared to placebo control.

16. The method of claim 11, wherein said administering effects a reduction in VLDL-C in the subject compared to placebo control.

17. The method of claim 11, wherein said administering effects reduction in fasting triglycerides of at least about 20% without increasing LDL-C in the subject compared to placebo control.

18. The method of claim 11, wherein each capsule comprises about 950 mg of ethyl eicosapentaenoate.

19. The method of claim 11, wherein each capsule comprises about 975 mg of ethyl eicosapentaenoate.

20. The method of claim 11, wherein each capsule comprises about 1 g of ethyl eicosapentaenoate.

\* \* \* \* \*